<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746105</url>
  </required_header>
  <id_info>
    <org_study_id>TS142-208</org_study_id>
    <nct_id>NCT04746105</nct_id>
  </id_info>
  <brief_title>A Clinical Pharmacology Study of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.</brief_title>
  <official_title>A Study to Evaluate the Respiratory Safety of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the respiratory safety of TS-142 in patients with mild obstructive sleep&#xD;
      apnea hypopnea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least square mean difference of Apnea hypopnea index (AHI) from placebo</measure>
    <time_frame>Day 1</time_frame>
    <description>AHI is a number of apnea and hypopnea events per hour during sleep determined by polysoãŽœography (PSG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Least square mean difference of the mean SpO2 in total sleep time from placebo</measure>
    <time_frame>Day 1</time_frame>
    <description>The SpO2 will be simultaneously measured with PSG. The mean SpO2 during sleep determined by PSG will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Patients With Mild Obstructive Sleep Apnea Hypopnea</condition>
  <arm_group>
    <arm_group_label>TS-142</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which subjects received TS-142 10 mg or The night when subjects received TS-142</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period in which subjects received placebo or The night when subjects received matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142</intervention_name>
    <description>Subjects received single-dose of 10 mg of TS-142 (oral tablet)</description>
    <arm_group_label>TS-142</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose-matched Placebo to TS-142</intervention_name>
    <description>Subjects received single-dose matched placebo to TS-142 (oral tablet)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese male and female, age 20 years or older at the time of informed consent&#xD;
&#xD;
          -  Patients who meet the Diagnostic and Statistical Manual of Mental Disorders, fifth&#xD;
             edition (DSM-5) criteria for obstructive sleep apnea hypopnea&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
          -  Patients who meet the Diagnostic and Statistical Manual of Mental Disorders, fifth&#xD;
             edition (DSM-5) criteria excepting obstructive sleep apnea hypopnea and insomnia&#xD;
             disorder&#xD;
&#xD;
          -  Patients who have clinically significant respiratory dysfunction (bronchiectasis,&#xD;
             emphysema, asthma, etc.) other than obstructive sleep apnea hypopnea&#xD;
&#xD;
          -  Patients with percutaneous arterial oxygen saturation (SpO2) &lt;94% by pulse oximetry at&#xD;
             visit 1&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Direcoter</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taisho Pharmaceutical Co., Ltd.</last_name>
    <phone>81-3-3985-1413</phone>
    <email>clinical-trials_CTG@taisho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

